Table 2.
Results of the efficacy parameters registered on the intended-to-treat (ITT) population (mean ± SD, n = 34 in each group)
| Parameter | Basal | 1 month | 2 month | 3 month |
|---|---|---|---|---|
| Muscular strength (Nm) | ||||
| Peak torque, extension at 240°/s | ||||
| Placebo | 64.1 ± 24.83 | 65.3 ± 23.73 | ||
| Mobilee™ | 65.4 ± 27.75 | 66.7 ± 27.12 | ||
| p value | 0.906 | |||
| Synovial effusion (mm) | ||||
| Placebo | 3.8 ± 2.15 | 2.7 ± 2.80 | ||
| Mobilee™ | 4.2 ± 2.3 | 1.6 ± 1.51 | ||
| p value | 0.029 | |||
| Pain VAS (cm) | ||||
| Placebo | 39.6 ± 4.86 | 36.1 ± 3.96 | 34.0 ± 3.85 | 31.9 ± 15.81 |
| Mobilee™ | 42.3 ± 5.67 | 36.7 ± 5.99 | 32.5 ± 4.96 | 21.1 ± 12.36 |
| p value | 0.278 | 0.005 | <0.001 | |
| Quality-of-life SF-36 | ||||
| Physical component (PCS-36) | ||||
| Placebo | 42.6 ± 10.26 | 44.5 ± 10.95 | 44.8 ± 10.56 | 44.0 ± 10.62 |
| Mobilee™ | 41.2 ± 9.34 | 42.9 ± 8.67 | 43.4 ± 9.13 | 45.5 ± 9.05 |
| p value | 0.727 | 0.824 | 0.093 | |
| Mental component (MCS-36) | ||||
| Placebo | 44.9 ± 12.79 | 47.5 ± 11.82 | 47.5 ± 12.69 | 49.5 ± 10.79 |
| Mobilee™ | 50.1 ± 8.12 | 50.4 ± 9.59 | 49.5 ± 9.97 | 50.2 ± 10.68 |
| p value | 0.881 | 0.876 | 0.295 | |
p values < 0.05 are highlighted in bold